TGFβ signaling is the major pathway regulating myoCAF differentiation, and different groups have shown that coadministration of anti-TGFβ with anti–PD-1/PD-L1 antibodies significantly improves response in preclinical tumor models (8, 13). This evidence concerns the gene CD274 and neoplasm.